Access Pharmaceuticals (OTCBB: ACCP) said Thursday it will be presenting its research on its oral insulin formulation at the 10th Annual Diabetes Technology Meeting held today in Maryland.
The research report, titled "Preclinical Studies with Cobalamin Nanoparticles for Oral Drug Delivery of Insulin", will review the progress made by Access scientists in developing the the technology CobOral for diabetics.
"We are continuing to explore additional collaborations to further the technology's promise in providing an effective and convenient method to control glucose levels in diabetic patients, and in treating other indications," said the senior vice president of research and development at Access, David Nowotnik.
During studies, the CobOral insulin-containing nanoparticle formulation provided a pharmacological response (lowering of blood glucose levels in an animal model of diabetes) equivalent to greater than 80% of that achieved by insulin delivered through injection.
Access said it also adapted this formulation for hGH (the human growth hormone), which showed that when delivered orally, there was more than 25% improvement in weight gain.
Last week, the company received a $245,000 grant from the US government for the insulin program.
Access' other products include MuGard, for the management of patients with mucositis, and ProLindac, currently in Phase II clinical testing of patients with ovarian cancer. The company rallied more than 2% on Thursday, trading at $3.15 as of 11:38am EST.
Disclosure: No positions